This enhancement in outcomes is particularly crucial in the early stages of the disease.[20] In addition, alectinib has also proven to be highly efficacious in advanced or metastatic ALK-positive NSCLC, specifically in stages IIIB and IV, where it has shown promising results in controlling disease progression and improving overall patient prognosis. The gene discussed is ALK; the disease is non-small cell lung carcinoma.